Table 2.
Primary and Secondary Endpoints (independent t-tests, two-way ANOVA).
| Omega-3 Fatty Acids (n = 50) (% Change from Baseline (95% CI)) |
Omega-3 Fatty Acids PPARG Polymorphism vs. Omega-3 Fatty Acids No PPARG Polymorphism | Placebo (n = 49) (% Change From Baseline (95% CI)) |
Omega-3 Fatty Acids PPARG Polymorphism vs. Placebo PPARG Polymorphism | Omega-3 Fatty Acids No PPARG Polymorphism vs. Placebo No PPARG Polymorphism | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PPARG Polymorphism (n = 21) | No PPARG Polymorphism (n = 29) | % Difference (95% CI) | p-Value | PPARG Polymorphism (n = 21) | No PPARG Polymorphism (n = 28) | % Difference (95% CI) | p-Value | % Difference (95% CI) | p-Value | |
| LDL-C | −15.4% (−19.8%, −11.0%) | −3.7% (−6.9%, −0.6%) | −11.6% (−19.3%, −4.0%) | p < 0.01 | −2.6% (−4.1%, −1.1%) | −2.9% (−5.1%, −0.8%) | −12.8% (−21.7%, −3.9%) | p < 0.01 | 0.2% (−5.0%, 5.4%) | p = 0.28 |
| Total cholesterol | −6.2% (−10.9%, −1.5%) | −1.4% (−3.4%, 0.7%) | −4.9% (−8.6%, −1.1%) | p = 0.23 | −1.4% (−3.3%, 0.4%) | −1.5% (−3.8%, 0.8%) | −4.8% (−13.6%, 4.1%) | p = 0.29 | 0.13% (−5.06%, 5.32%) | p = 0.61 |
| HDL-C | 6.7% (2.1%, 11.3%) | 4.4% (0.1%, 8.6%) | 2.3% (−3.8%, 8.4%) | p = 0.21 | 3.23% (−1.3%, 7.3%) | 5.0% (0.6%, 9.5%) | 3.4% (−5.4%, 12.3%) | p = 0.18 | −0.7% (−5.9%, 4.5%) | p = 0.14 |
| Triglycerides | −21.3% (−26.5%, −16.2%) | −8.5% (−12.8%, −4.3%) | −12.8% (−22.2%, 3.4%) | p < 0.01 | −1.9% (−4.7%, 0.9%) | −2.1% (−4.8%, 0.5%) | −13.4% (−22.1%, −4.8%) | p < 0.01 | −7.4% (−14.0%, −0.8%) | p = 0.21 |
| hsCRP | −5.8% (−32.5%, 20.9%) | −2.1%(−24.1%, 19.9%) | −3.7% (−8.4%, 1.0%) | p = 0.56 | −3.9%(−21.6%, 13.8%) | −6.1% (−23.9%, 11.7%) | −1.9% (−46.3%, 42.5%) | p = 0.82 | −4.0% (−32.3%, 24.3%) | p = 0.72 |